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a  b  s  t  r  a  c  t
Human  prolactin  (hPRL)  is  a  polypeptide  hormone  occurring  in  the  non-glycosylated  (NG-hPRL)  and
glycosylated  (G-hPRL)  forms,  with  MM of  approximately  23 and  25 kDa,  respectively.  It has  a  single,
partially  occupied  N-glycosylation  site  located  at Asn-31,  which  makes  it a particularly  simple  and  inter-
esting  model  for  glycosylation  studies.  The  bioactivity  of  G-hPRL  is  lower  than  that  of NG-hPRL  (by  ca.
4-fold) and its  physiological  function  is not clear.  However,  carbohydrate  moieties  generally  play impor-
tant roles  in  the  biosynthesis,  secretion,  biological  activity,  and  plasma  survival  of  glycohormones  and
can  vary depending  on  the  host  cell. The  main  objective  of this  study  was  to determine  the  N-glycan
structures  present  in  native,  pituitary  G-hPRL  and  compare  them  with  those  present  in the recombi-
nant  hormone.  To  obtain  recombinant  G-hPRL,  genetically  modiﬁed  Chinese  hamster  ovary  cells  (CHO),
adapted  to growth  in  suspension,  were  treated  with  cycloheximide,  thus  increasing  the  glycosylation  site
occupancy  from  5.5%  to  38.3%,  thereby  facilitating  G-hPRL  puriﬁcation.  CHO  cell-derived  G-hPRL  (CHO-G-
hPRL)  was  compared  to pituitary  G-hPRL  (pit-G-hPRL)  especially  with  regard  to N-glycoproﬁling.  Among
the main  differences  found  in  the  pituitary  sample  were  an  extremely  low  presence  of  sialylated  (1.7%)
and  a high  percentage  of  sulfated  (74.0%)  and  of  fucosylated  (90.5%)  glycans.  A  ∼6-fold  lower  in vitro
bioactivity  and  a higher  clearance  rate  in  mice  were also  found  for  pit-G-hPRL  versus  CHO-G-hPRL.  N-
Glycan  proﬁling  proved  to  be  a useful  and  accurate  methodology  also for MM  and carbohydrate  content
determination  for  the two  G-hPRL  preparations,  in good  agreement  with  the  values  obtained  directly  via
MALDI-TOF-MS.
© 2014  Elsevier  B.V.  All  rights  reserved.. IntroductionHuman prolactin (hPRL) is a pituitary-secreted polypeptide hor-
one whose essential role is on mammopoiesis. In addition, it
xerts many other physiological actions on behavior and brain
Abbreviations: CDG, congenital disorders of glycosylation; CHO, Chinese hamster
vary; CHX, cycloheximide; hPRL, human prolactin; HPSEC, size-exclusion HPLC;
ALDI-TOF-MS, matrix assisted laser desorption ionization time-of-ﬂight mass
pectrometry; MM,  molecular mass; Mr,  relative molecular mass; NHPP, National
ormone and Pituitary Program; PAGE, polyacrylamide-gel electrophoresis; SDS,
odium dodecyl sulfate; RP-HPLC, reverse-phase HPLC; tR, retention time.
∗ Corresponding author at: Instituto de Pesquisas Energéticas e Nucleares, IPEN –
NEN/SP, Biotechnology Center, Av. Prof. Lineu Prestes 2242, São Paulo, SP 05580-
00, Brazil. Tel.: +55 11 3133 9693; fax: +55 11 3133 9694.
E-mail address: crsoares@ipen.br (C.R.J. Soares).
ttp://dx.doi.org/10.1016/j.jbiotec.2014.11.034
168-1656/© 2014 Elsevier B.V. All rights reserved.in general and on metabolism, immune responses and electrolyte
balance (Bernichtein et al., 2010; Gofﬁn et al., 2002). Several exper-
imental studies have deﬁned this hormone as the “regulator of
maternal behavior”, but recent studies also consider it to be a can-
didate “regulator of paternal behavior” (Gettler et al., 2012). The
interest in hPRL stems from its clinical importance for women with
lactation problems and infertility, as well as from the fact that ele-
vated circulating levels or locally produced hPRL are associated
with increased risks of breast and prostate cancer (Bernichtein et al.,
2010; Fernandez et al., 2010; Suzuki et al., 2012; Tworoger et al.,
2004).
Human prolactin (hPRL) is a 199 amino acid-polypeptide with
a single potential N-glycosylation site located at Asn-31, which is
partially (5–30%) occupied in the native pituitary form or in the
recombinant form of the hormone (Heller et al., 2010; Price et al.,
1995; Sinha, 1995; Soares et al., 2000, 2002). It thus exhibits the
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implest type of glycosylation macroheterogeneity: one protein
opulation with and one without a single N-linked glycan (Heller
t al., 2010; Shelikoff et al., 1994). This makes it particularly ideal
or glycosylation studies, especially considering the complexity of
lycan composition and the challenging task of the simultaneous
ccurate determination of: (i) protein concentration; (ii) oligosac-
haride structures (i.e., the variation of the glycoform proﬁle); and
iii) the glycosylation site occupancy of glycoproteins in general
Apweiler et al., 1999; Desaire, 2013; Lin et al., 2012; Pan et al.,
012; Petrescu et al., 2004).
Glycosylated hPRL (G-hPRL) has an approximately 4-fold lower
otency compared to the non-glycosylated form (NG-hPRL), show-
ng reduced lactotrophic and mitogenic activity (Heller et al.,
010; Price et al., 1995; Shelikoff et al., 1994; Sinha, 1995).
lthough it has been considered to be the major post-translational
odiﬁcation of NG-hPRL, with which it is co-secreted from child-
ood to the end of puberty, its physiological signiﬁcance is still
ot yet well elucidated (Fideleff et al., 2012; Freeman et al.,
000).
Because it is such a simple monoglycosylation model, G-
PRL has been chosen to develop a methodology for determining
ligosaccharide structures and glycosylation site occupancy via gly-
oproﬁling analysis. After it has been validated, this methodology
hould then be applicable also to more complex polyglycosylated
roteins. The importance of correctly knowing these parameters
as been emphasized in the literature. Thus, comparative quanti-
ative proﬁling of a glycoproteome and the accurate quantiﬁcation
f its glycosylation site occupancy have been related to folding,
rafﬁcking, initiation of inﬂammation, and host defense, as well
s to disease states such as congenital disorders of glycosylation
CDG). These latter are a family of rare, inherited metabolic syn-
romes that affect the synthesis, transfer or processing of glycans
nd that cause motor and intellectual disability and variable multi-
ystemic symptoms. In type-I CDG the early steps of glycosylation
re impaired, resulting in unoccupied glycosylation sites; in type-
I CDG the defects do not inﬂuence occupancy, but rather glycan
rocessing (Barone et al., 2009; Fogli et al., 2012; Losfeld et al.,
012; Pan et al., 2012; Petrescu et al., 2004; Tian and Zhang,
010).
The present study is based on suspension-adapted prolactin-
ecreting CHO cells, cultivated in spinner ﬂasks and incubated in the
resence of cycloheximide in order to increase the proportion of G-
PRL in the total amount of prolactin and facilitate its puriﬁcation.
uriﬁed G-hPRL, which is now a 100% occupied monoglycosylated
rotein, is then extensively characterized by SDS-PAGE, Western
lotting, reverse-phase and size-exclusion HPLC, in vitro bioassay,
harmacokinetic analysis, MALDI-TOF-MS relative molecular mass
Mr) determination and, ﬁnally, N-glycan1 proﬁling. Our recom-
inant preparation (CHO cell-derived) is compared to the native
ituitary (lactotrophic cell-derived) preparation, using a well-
nown reference from the National Hormone and Pituitary Program
NHPP, USA). Accurate MALDI-TOF-MS molecular mass determina-
ion was employed to conﬁrm that the glycoproﬁling approach is
ndeed useful for correctly determining, besides the monosaccha-
ide composition of each glycan, also the average glycan mass, the
hole glycoprotein mass and, consequently, the percent molecu-ar weight exclusively due to the carbohydrate moiety in the two
reparations.
1 Abbreviations for N-glycans were made by not considering the basic pen-
asaccharidic nucleus (“zero”) and adding all other monosaccharides, as stated in
he ﬁgures, in the following order: Man  (M); GlcNAc (N); Gal (G); GalNAc (Gn);
euAc/sialic acid (S); Fuc (F). So, for example, NeuAc1 Gal1 GlcNAc2 Fuc1 + Man3
lcNAc2, becomes N2G1S1F1.echnology 202 (2015) 78–87 79
2. Materials and methods
2.1. Cell line
The clone expressing hPRL, obtained in our laboratory and uti-
lized in this study, was  derived from CHO dhfr-cells (DUKX-B11)
that had been transfected with the vector pEDdc-hPRL (Soares et al.,
2000) and adapted to suspension growth in serum-free medium
(Arthuso et al., 2012).
2.2. G-hPRL production in spinners
For laboratory production, 250 ml  spinner ﬂasks containing
100 ml  of CHO-S-SFM II medium, supplemented with antibiotics
(50 unit ml−1 penicillin; 50 g ml−1 streptomycin, 40 g ml−1 gen-
tamycin and 1.25 g ml−1 amphotericin B), were utilized. Cells
were cultured at 37 ◦C under 5% CO2, stirring at ∼80 rpm. When a
density of 1 × 106 cell ml−1 was obtained, the total volume of condi-
tioned medium (100 ml)  was centrifuged at 400 × g and substituted
with fresh medium, with the initial cell concentration ﬁxed at
∼1 × 106 cell ml−1. In this phase, CHX (0–1 g ml−1, depending on
the experiment) was added and the conditioned medium, collected
daily by centrifugation at 400 × g, was replaced with a fresh one.
This procedure was  repeated for 10 days. The collected medium
was stored at −40 ◦C.
2.3. Gel electrophoresis and Western blotting
Discontinuous SDS-PAGE, based on 15% polyacrylamide gels,
was carried out under non-reducing conditions as described by
Laemmli (1970). Coomassie Brilliant Blue G-250 (USB, Cleveland,
OH) or silver nitrate was  used for staining; the molecular mass
markers were from GE Healthcare Bio-Sciences (Uppsala, Sweden).
For the Western blotting the proteins were transferred from the
polyacrylamide gel to nitrocellulose membrane by the semi-dry
transfer technique, probed with polyclonal anti-hPRL antiserum
produced in rabbit (1:5000) and with horseradish peroxidase-
conjugated anti-rabbit IgG (1:10,000). Visualization of proteins was
performed with Luminata Forte (Millipore) on X-ray ﬁlm.
2.4. HPSEC
A Shimadzu Model SCL-10A HPLC apparatus coupled to a SPD-
10AV UV detector (Shimadzu, MD,  USA) was  used, employing the
Class VP software, also from Shimadzu. For HPSEC, a TosoHaas
(Montgomeryville, PA, USA) G2000 SW column (60 cm × 7.5 mm
i.d., particle size of 10 m and pore size of 125 A˚) coupled to a
7.5 cm × 7.5 mm ID SW guard column was  used. The mobile phase
was 0.025 M ammonium bicarbonate, pH 7.0, with a ﬂow-rate of
1.0 ml  min−1 (Dalmora et al., 1997).
2.5. G-hPRL puriﬁcation
The G-hPRL present in the conditioned culture medium was
puriﬁed using a two-step puriﬁcation method: SP-Sepharose Fast
Flow followed by a C4 Grace-Vydac 214TP54 (25 cm × 4.6 mm ID,
pore diameter of 300 A˚ and particle diameter of 5 m)  RP-HPLC col-
umn, used for preparative purposes. Brieﬂy, conditioned medium
(2000 ml)  was adjusted to pH 5.0 using acetic acid. The material was
then applied (5 ml  min−1) onto a 10 cm × 2.6 cm ID glass column
packed with SP-Sepharose Fast Flow (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) that had been previously equilibrated in
50 mM sodium acetate (pH 5.0). UV absorbance was  monitored at
280 nm.  After washing with the same buffer, the column was eluted
with 50 mM  sodium acetate (pH 5.0), 90 mM NaCl. Human PRL (G-
hPRL and NG-hPRL) was then eluted from the column with 25 mM
80 M.V.N. Capone et al. / Journal of Biotechnology 202 (2015) 78–87
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The analysis of the N-glycan structures was  carried out by Pro-
teodynamics SARL (Clermont-Ferrand, France). Two  samples wereig. 1. Western blot analysis of hPRL from CHO cells conditioned media obtained
resence of different concentrations of cycloheximide; hPRL, internal reference pre
he  presence of 0.6 g ml−1 of cycloheximide; control, product obtained without cy
epes (pH 8.0). All fractions containing hPRL were analyzed by SDS-
AGE and the most concentrated fractions pooled and loaded onto a
race-Vydac C4 214 TP54 RP-HPLC column, equilibrated in 0.05 M
odium phosphate buffer containing 45% acetonitrile. The maxi-
um  volume applied for each RP-HPLC preparative run was 6 ml
3× 2 ml  applied sequentially). A washing step with the same buffer,
arried out over 60 min, was  followed by the elution of G-hPRL with
0% acetonitrile, pH 7.0, at a ﬂow rate of 0.5 mL  min−1 for 30 min
t 30 ◦C. A G-hPRL ﬁnal pool, derived from RP-HPLC puriﬁcation,
as analyzed by SDS-PAGE and HPSEC and stored at −80 ◦C, before
yophilization, for N-glycan structure analysis (glycoproﬁling).
.6. In vitro bioassays
The biological activities of puriﬁed G-hPRL were determined
y the Nb2 lymphoma cell-proliferation assays, as previously
escribed (Glezer et al., 2006), against the First WHO  Refer-
nce Reagent of recombinant hPRL lyophilized in ampoules coded
7/714. This preparation includes NG-hPRL and G-hPRL and its
iological activity (57.2 IU mg−1) was established thanks to a WHO-
IBSC International Collaborative Study, also carried out with
articipation of our laboratory (Rafferty et al., 2001). The curves
ere constructed after subtraction of the medium control..7. Pharmacokinetic analysis
Single doses (2 g) of the different G-hPRL preparations were
dministered to BALB/c mice (three animals per group) byinner ﬂasks. (A) Samples obtained on the 2nd and 3rd day of production in the
on of E. coli-derived hPRL. (B) Samples obtained during a 6-day production cycle in
ximide addition.
intraperitoneal injection. Blood was  withdrawn from the retro-
orbital cavity at 30, 60, 90, 120 and 180 min post injection and
serum samples were obtained by incubating 20 min  at 37 ◦C, then
20 min  at 4 ◦C and centrifuging 7 min  at 2500 × g. Serum G-hPRL
concentrations were determined using a human PRL double anti-
body ELISA kit (Diagnostic Systems, Ltd., Novogorod, Russia). No
cross-reaction was  detected with endogenous mouse-PRL and its
response to G-hPRL was about 40% less than that to NG-hPRL.
2.8. Mass spectrometry for molecular mass determination
MALDI-TOF-MS molecular mass determinations of hPRL (NG-
hPRL and G-hPRL) were carried out by American International
Biotechnology (AIBio Tech) Services, (Richmond, VA, USA) using
sinapinic acid (SA) as the matrix and a Voyager-DE BioSpectrometry
Workstation from Applied Biosystems (Foster City, CA, USA).
2.9. N-glycosylation proﬁling by MALDI-TOF-MSanalyzed: recombinant G-hPRL IPEN produced in our laboratory
and a pituitary G-hPRL obtained from Dr. A.F. Parlow of the National
Hormone and Peptide Program (NHPP) (Torrance, CA, USA), both
lyophilized.
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Fig. 2. (A) SP-Sepharose FF puriﬁcation of hPRL from 1 l of CHO cell culture medium obtained in the presence of 0.6 g ml−1 of cycloheximide. (B) SDS-PAGE analysis of
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.10. Glycosidase digestion and permethylation of N-glycans
Proteins (260 g of CHO-derived G-hPRL and 340 g of pituitary
-hPRL) were denatured in 0.5% sodium dodecyl sulphate (SDS) and
% -mercaptoethanol (90 ◦C, 10 min) and deglycosylated by enzy-
atic digestion treating for 15 h at 37 ◦C with 20 units PNGase F
lot 13643021) from Roche Applied Science (Mannheim, Germany),
ccording to Fogli et al. (2012). Deglycosylation was monitored on
 NuPage gradient of 4–12% MES  (Invitrogen) by Coomassie blue
taining.
A speciﬁcally adapted permethylation protocol based on Yu et al.
2009) was employed to separate sulfated from non-sulfated or
hosphorylated N-glycans of pituitary G-hPRL. After permethyla-
ion, the N-glycans were puriﬁed on C18 Sep Pak Plus (Waters,
ilford, MA)  by step-elution with 25% acetonitrile and 50% ace-
onitrile. The 25% acetonitrile fraction contains sulfated glycans,
resent only in the pituitary product, while non-sulfated and phos-
horylated glycans are found in the 50% acetonitrile fraction. Eluted
-glycans were lyophilized before MALDI-TOF-MS analysis.
.11. MALDI-TOF analysis of N-glycans
Mass spectra of permethylated N-glycans resuspended in 20 l
f 50% methanol/water were acquired in the positive reﬂector
ode (m/z range 1000–5000 Da) on MALDI-TOF DE PRO (ABsiex,
nc., Framingham, MA)  with DHB as matrix (10 mg  ml−1, ratio 1:1).
The spectra were obtained by accumulation of 500 shots and
ere calibrated with an external standard. MALDI-MS data werePRL, based on 15% polyacrylamide gels under non-reducing conditions and stained
 corresponding to fractions # 42–45 and to the pool of these fractions; NG-hPRL, E.
processed using DataExplorer 4.0 to generate ﬁles listing m/z
values and to compare intensities. Interpretation of glycan struc-
tures corresponding to monoisotopic masses was performed using
EXPAZY GlycoMod tool (http://ca.expasy.org/tools/glycomod/) and
GlycoWorkBench. MALDI-PSD fragmentation was performed on
selected ions to conﬁrm structures.
To obtain a relative quantiﬁcation comprising all N-glycans
present on the pituitary-derived protein, a correlation factor
between the spectra of sulfated and native glycans was  calculated.
This correlation factor was  determined either by using an inter-
nal calibration standard to normalize peak intensities of the two
spectra or by mixing the two  glycan fractions and using the ratio
between peak heights of the dominant peaks of each fraction.
2.12. Monosaccharide molar ratio determination on the basis of
glycoproﬁling
The glycoproﬁling and the relative percent intensity of each
determined glycan were used to calculate the average N-glycan
mass that is present in the G-hPRL molecule. This mass, added to the
theoretical molecular mass of NG-hPRL (22,897.75 Da), provided a
good estimate of the G-hPRL molecular mass and of the percent
by weight of the carbohydrate moiety. Through this stoichiomet-
ric approach, the percentage of each monosaccharide and its molar
ratio, referred to the G-hPRL molecule, were also calculated (see
Supplementary Material).
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pplied  in each run. HPSEC analysis of: (B) the main peak eluted from RP-HPLC; (C)
. Results and discussion
.1. Prolactin synthesis inhibition and puriﬁcationConsidering previous work reporting the effects of cyclohex-
mide on hPRL-secreting, adherent CHO cell culture (Heller et al.,
010) the effects of this drug were investigated under the present
ig. 4. SDS-PAGE analysis under non-reducing conditions and stained with silver
itrate, of all puriﬁcation steps of CHO-G-hPRL. (1) Molecular mass markers; (2)
0-day production conditioned medium; (3) main peak eluted from SP-Sepharose;
4)  pure CHO-G-hPRL obtained after RP-HPLC elution; (5) puriﬁed CHO-G-hPRL
fter lyophilization; (6) pit-G-hPRL from NHPP; (7) CRS-WHO containing C127-G-
PRL + C127-NG-hPRL; and (8) internal reference preparation of E. coli-NG-hPRL.n) used in the preparative mode: 3 × 2 ml from the main SP-Sepharose peak were
HO containing C127-G-hPRL + C127-NG-hPRL; and (D) pit-G-hPRL from NHPP.
culture conditions: suspension-adapted cells, spinner ﬂask culture
and serum-free medium, as described by Arthuso et al. (2012). The
optimal cycloheximide concentration to be added to the culture
medium in order to obtain the highest glycosylation site occu-
pancy was  determined by Western blotting, as shown in Fig. 1A.
The increase in cycloheximide concentration produced a remark-
able reduction in the amount of NG-hPRL, while G-hPRL remained
practically the same. With 1 g ml−1 cycloheximide, however, both
isoforms declined dramatically. The concentration of 0.6 g ml−1
was thus chosen for G-hPRL synthesis, in line with that adopted
by Heller et al. (2010). This condition was also used for the 6-day
production cycle illustrated in Fig. 1B, which shows that the drug
was already fully effective on day 1. A third, weaker band was also
observed in this experiment: probably a glycosylated isoform.
Fig. 5. Nb2 cell proliferation bioassay comparing the biological activities of puriﬁed
CHO-G-hPRL (--) and pit-G-hPRL from NHPP (--) with the International Standard
of C127-derived hPRL WHO  97/714, containing C127-G-hPRL + C127-NG-hPRL (--).
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Table  1
Pharmacokinetic parameters for CHO-derived and pituitary G-hPRL.
Preparation t1/2 (min) AUC (ng min  ml−1)
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Fig. 6. NuPAGE gradient electrophoresis under reducing conditions and stainedCHO-derived G-hPRL 36.0 6279.5
Pituitary G-hPRL 34.5 2615.5
To evaluate cycloheximide effects on cell growth and viabil-
ty, two spinner ﬂasks, with or without cycloheximide addition,
ere compared in a 10-day production cycle, replacing the culture
edium daily, as in a regular production scheme. A small decrease
∼6%) in cell concentration was observed upon cycloheximide addi-
ion, conﬁrming that the concentration chosen was only slightly
oxic to the cells (data not shown).
The puriﬁcation process of recombinant G-hPRL consisted of
wo steps: an initial concentration/puriﬁcation step carried out
y cation exchange chromatography on SP-Sepharose FF and a
econd step based on a small analytical RP-HPLC column, used
n the preparative mode. The cation exchanger provided a main
eak containing both NG-hPRL and G-hPRL (Fig. 2A), as con-
rmed by SDS-PAGE analysis (Fig. 2B). Western blotting, moreover,
onﬁrmed that the high MM material observed in SDS-PAGE
s not related to prolactin (Fig. 2C). Qualitative and quantita-
ive RP-HPLC analysis carried out after this step showed the
xpected marked decrease (∼16-fold) of NG-hPRL (from 3088 ± 80
o 190 ± 55 g ml−1, n = 3) upon cycloheximide addition, while G-
PRL decreased only ∼30% (from 178 ± 75 to 118 ± 52 g ml−1,
 = 3). The reduction in elongation rate provoked by cycloheximide
ddition thus increased the N-glycosylation site occupancy from
.5% to 38.3%. Preparative RP-HPLC, carried out as in previous work
or mouse prolactin puriﬁcation (Suzuki et al., 2012), had the advan-
age of using a small column (25 cm × 4.6 mm i.d.) to process a
elatively large volume (about 20 ml)  of the SP-Sepharose eluted
eak in only three runs, obtaining a separation between CHO-G-
PRL and CHO-NG-hPRL (Fig. 3A).
.2. Characterization of CHO-derived G-hPRL
In a relatively short time preparative RP-HPLC provided a >90%
ure product. This is shown in analytical HPSEC (Fig. 3B) in which
he retention time (tR) of the main peak of G-hPRL is well preserved
ompared with the CRS (C127-derived chemical research standard
 WHO) containing C127-G-hPRL + C127-NG-hPRL (Fig. 3C) and
ith human pituitary G-hPRL (Fig. 3D), with only minor peaks due
o buffer components (tR > 20 min) and probably a small amount of
ggregate (tR = 11 min).
Silver stained SDS-PAGE (Fig. 4) was employed to conﬁrm the
urity of G-hPRL IPEN obtained via this process, together with the
nalysis of all intermediate steps. Although it is almost impossible
o detect the two PRL isoforms in the conditioned medium (lane
), they can be very clearly seen in the SP-Sepharose eluted peak
lane 3). A band of RP-HPLC-puriﬁed G-hPRL is then visible in lane 4
nd in the ﬁnal lyophilized product (lane 5), again with a very small
mount of the faster-running band mentioned above. Interestingly,
he band of pituitary G-hPRL with an apparent lower molecular
ass can be observed in lane 6 and, in lane 7, C127-G-hPRL from
HO-CRS with an intermediate mass. Finally, lane 8 conﬁrms the
onstant position of NG-PRL.
The biological activity of CHO-G-hPRL, determined by the Nb2
ell in vitro bioassay, was 20.4 ± 1.7 IU mg−1 (n = 2), i.e., ∼3-fold
ower than that deﬁned for NG-hPRL 63.7 IU mg−1 (Rafferty et al.,
001). This conﬁrms literature values, including that reported by
eller et al. (2010) for a similar CHO cell-derived G-hPRL prepa-
ation (14.7 ± 5.7 IU mg−1). The potency of pit-G-hPRL from NHPP,
n the other hand, was 3.6 ± 0.2 IU mg−1, i.e. 5.7-fold lower than
hat of CHO-G-hPRL. Typical Nb2 assay curves, including that ofwith Coomassie Brilliant Blue, showing the deglycosylation of: (A) pit-G-hPRL from
NHPP and (B) CHO-G-hPRL. Lane 1, G-hPRL; lane 2, G-hPRL treated with peptide-N-
glycosidase F (PNGase F).
the International Standard of Recombinant hPRL (WHO 97/714)
used for potency determination, are shown in Fig. 5. It is important
to note, however, that the Nb2 proliferative assay, even being the
most widely used for human prolactin bioactivity determination,
only measures a particular type of activity. It would be interesting
to determine and compare, for both preparations, G-hPRL activity
related to other physiological actions such as, for example, milk
protein induction or salt reuptake in the kidney. Quite intriguing
is also the fact that pit-G-hPRL shows an ∼6-fold lower bioactiv-
ity than CHO-G-hPRL. We  do not have a ready explanation for this,
unless we  think of the possible inﬂuence of the different carbo-
hydrate moiety at the receptor level. We  found, in previous work,
differences of the same order (up to 3.4–4.2-fold) when compar-
ing pituitary with CHO-derived hTSH (Damiani et al., 2013). In that
case, however, an in vivo bioassay was  utilized and there was cer-
tainly an inﬂuence on the clearance rate due to the presence of
terminal GalNAc-4-SO4 and 1,4-linked GalNAc in the pituitary
preparation.
A preliminary pharmacokinetic study was carried out by com-
paring the in vivo clearance rate of CHO-derived and pituitary
G-hPRL in normal mice. Table 1 shows that there is a tendency
to an increased half-life (t1/2) and area-under-the curve (AUC) for
the recombinant preparation. Conﬁrming our previous data on
analogous hTSH preparations (Damiani et al., 2013), the shorter cir-
culatory half-life of pituitary G-hPRL is probably due, among other
factors, to the presence of the terminal sequence GalNAc-4-SO4 that
determines a removal of G-hPRL from the circulation by a speciﬁc
receptor expressed by endothelial cells lining the sinusoids of the
liver (Baenziger, 2003; Mi  et al., 2008). The presence, however, of
74% sulfated N-glycans in pit-G-hPRL should have determined, in
our opinion, a much higher clearance rate.3.3. N-glycoproﬁling of pituitary and recombinant G-hPRL
Our CHO cell-derived G-hPRL was then compared with native
pituitary G-hPRL with respect to the N-glycan structures. The
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Fig. 7. N-glycan structures of pit-G-hPRL from NHPP. (A) Non-sulfated N-glycans; (B) sulfated N-glycans. The relative percent intensity is indicated below each glycan
structure. See the text for N-glycan nomenclature.
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lFig. 8. N-glycan structures of CHO-G-hPRL. The relative percent intensity is ind
ccupancy, now 100%, was re-conﬁrmed via NuPAGE gradient elec-
rophoresis after glycosidase digestion, as shown in Fig. 6 for the
ative and recombinant preparations. In the native preparation,
he larger, more heterogeneous G-hPRL band was totally converted
nto a narrower band of NG-hPRL by deglycosylation. In the case of
he recombinant preparation, however, a small amount of NG-hPRL
ppears as a contaminant, even before deglycosylation (Fig. 6B).
igs. 7 and 8 show the N-glycosylation proﬁling and relative inten-
ities obtained by MALDI-TOF-MS after glycosidase digestion and
-glycan permethylation of native and CHO-cell-derived G-hPRL,
espectively. The quantitative monosaccharide determination for
oth preparations and the corresponding molar ratios derived from
-glycoproﬁling shown in Table 2 are based on a stoichiomet-
ic calculation which considered the molecular mass and relative
ntensities of each detected N-glycan, as described in Section 2.
he average glycan mass, also calculated on the basis of the same
arameters, was 2118.0 Da for CHO cell-derived and 1837.8 Da for
actotroph cell-derived G-hPRL (Table 3). See also the Supplemen-
ary Material on “Mass spectral Data”.In native G-hPRL (Fig. 7 and Table 2), some high-mannose
∼6%), mostly complex structures, frequently fucosylated (90.5%)
nd rarely sialylated (1.7%), are present. As expected, since human
actotroph cells have galactosyl- and sulpho-transferases that are below each glycan structure. See “Abbreviations” for N-glycan nomenclature.
absent in CHO cells, the glycans of the former have a high percent-
age of sulfated glycans (74%) and a signiﬁcant amount of N-acetyl
galactosamine (GalNAc), sulphated or not: 1.31 mole mole−1. The
amount of galactose is quite low (0.081 mole mole−1) and that of
sialic acid extremely low (0.02 mole mole−1). The most abundant
N-glycans are of the biantennary type: N2Gn2F2SO4 (33.8%) and
N2Gn2F1(SO4)2 (28.1%).
CHO cell-derived G-hPRL (Fig. 8 and Table 2) has a higher per-
centage of high-mannose forms (∼13%), mostly complex structures,
obviously no GalNAc or sulfated glycans, and much higher amounts
of galactose (1.62 mole mole−1) and sialic acid (1.34 mole mole−1).
The most abundant N-glycans are also of the biantennary type:
N2G2S2F1 (56%) and N2G2S1F1 (12%). There is also a small presence
(1.1%) of triantennary structures, not found in the native prod-
uct. Preliminary data on N-glycoproﬁling for CHO-derived G-hPRL
IPEN obtained without cycloheximide, conﬁrmed a similar distri-
bution for the most abundant N-glycan forms, with a relatively
higher presence of galactose (1.95 mole mole−1) and sialic acid
(1.74 mole mole−1), all other parameters being practically unal-
tered.
Post source decay (PSD) fragmentation analysis of selected
N-glycans, as for example of the two  most abundant sulfated gly-
cans presented in Fig. 7B (see Supplementary Material), was  also
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Table  2
Monosaccharide/G-hPRL molar ratio determination with basis on glycoproﬁling.
CHO cell-derived G-hPRLa Native pituitary G-hPRLb
Fraction of
glycan mass (%)
Monosaccharide weight
contribution (Da)
Mole/G-hPRL
mole
Fraction of
glycan mass (%)
Monosaccharide weight
contribution (Da)
Mole/G-hPRL mole
Fuc 5.03 106.5 0.73 10.10 185.6 1.27
Gal  NAc – – – 14.51 266.7 1.31
Glc  NAc 35.70 756.1 3.72 39.94 734.0 3.61
Gal  12.42 263.1 1.62 0.720 13.2 0.081
Man  28.04 593.9 3.66 30.30 556.8 3.43
SA  18.38 389.3 1.34 0.323 5.94 0.020
a Considering the N-glycan mass = 2118.0 Da.
b Considering the N-glycan mass = 1837.8 Da.
Table 3
Molecular mass of CHO cell-derived, C127 cell-derived and native pituitary (lactotroph-derived) glycosylated prolactin, determined via N-glycoproﬁling analysis and
compared to MALDI-TOF-MS determinations.
Origin of the preparation Via N-glycoproﬁling Via MALDI-TOF-MS
Average N-glycan
mass (Da)
G-hPRL MM
(Da)
Carbohydrate
moiety (%)
NG-PRL (Mr) G-PRL (Mr) Carbohydrate
moiety (%)
Difference between MM
and Mr for G-hPRL (%)
CHO cells 2118.0 25016a 8.5b 22889c 24970c 8.3e +0.18
C127  cells – – – 22880c 25139c 9.0e –
Human lactotrophs 1837.8 24736a 7.4b 22974d 24903d 7.7e −0.67
a Calculated by adding the N-glycan mass to the calculated NG-hPRL mass of 22,897.75 (Wu et al., 2003).
b Calculated as a percent of the average glycan mass on G-hPRL MM.
c
n
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ac Data from Heller et al. (2010).
d Present work.
e Calculated on the basis of NG-hPRL and G-hPRL Mr.
arried out to further determine their structure, ﬁnding, though,
o unusual ions. On the other hand the immunogenic Lewis X
Lex) motif GalGlcNAcFuc (Hashii et al., 2005; Lehr et al., 2006) was
pparently present in the non-sulfated glycan N2G2F2 (Fig. 7A).
It is noteworthy that these are the ﬁrst data on N-glycan struc-
ures that have been reported for G-PRL of either pituitary or
ecombinant origin. Price et al. (1995) inferred the monosaccharide
omposition of recombinant G-hPRL from oligosaccharide masses
range: 1972–2696) determined by electrospray ionization mass
pectroscopy (ESI-MS), masses that are typical of biantennary and
riantennary complex oligosaccharides with different degrees of
ialylation and fucosylation. Despite using a product of different
rigin (CHO versus C127 cells), our more detailed analysis conﬁrms
heir preliminary conclusion.
ig. 9. MALDI-TOF-MS analysis of pit-G-hPRL from NHPP, including a certain
mount of pit-NG-hPRL.3.4. Molecular mass determination based on N-glycoproﬁling and
MALDI-TOF-MS analysis
In Fig. 9 we report the MALDI-TOF-MS determination carried out
on native pituitary prolactin from NHPP, which shows the relative
molecular mass (Mr) of G-hPRL and the presence of NG-hPRL as
a contaminant. The exceptional accuracy and precision offered by
this methodology is indicated by the present data on pituitary NG-
hPRL and at least six previous determinations of the molecular mass
of CHO-, C127- or Escherichia coli-derived NG-hPRL (Heller et al.,
2010; Soares et al., 2006, 2008). The average inter-assay and inter-
preparation molecular mass of this protein was  22,910.34 ± 32.22
(CV = 0.14%, n = 6), which is only 0.055% higher than the theoreti-
cal molecular mass of 22,897.75 Da calculated from the amino acid
sequence (Wu et al., 2003) and 0.3% lower than the mass of pituitary
NG-hPRL determined in the present work via MALDI-TOF-MS.
In Table 3 the molecular mass (MM)  of both preparations of
G-hPRL, determined on the basis of glycoproﬁling and from the cal-
culated theoretical mass of NG-hPRL, are reported in comparison
with MALDI-TOF-MS Mr  determinations for NG-hPRL and G-hPRL
of different origins. There is good agreement between the two dif-
ferent analytical approaches for both the molecular mass and the
percent carbohydrate.
4. Conclusions
CHO-derived human prolactin, a simple model of a monoglyco-
sylated protein, was  obtained with greatly increased glycosylation
site occupancy via cycloheximide addition to the culture media. G-
hPRL was  then puriﬁed and extensively characterized, comparing
its bioactivity, clearance rate, N-glycan structures, monosaccharide
composition and molecular mass to those of the native hormone.
N-glycoproﬁling, together with MALDI-TOF-MS molecular mass
determination, proved to be extremely useful tools whose appli-
cation can be readily extended to the glycan structure analysis
and glycosylation site occupancy determination of polyglycosy-
lated proteins. We emphasize that, when looking for the biological
of Biot
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ctivity or in vivo action of human glycosylated prolactin or of
ther glycoprotein hormones, especially when used as biopharma-
euticals, one must always consider that CHO-derived material is
learly not identical to the native, pituitary material.
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